Pharma's Almanac

4647 Articles Available

1 194

Microbiome

Evaluating Microbiome Therapies with Intestinal Cell Models

PAO-10-20-CL-02

Phase III

Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma

PR-M10-20-14

Strategy

Vetter Continues its Long-term Investment Strategy to Sustain Future Growth

PR-M10-20-13

COVID-19

Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of an Inhaled Treatment for Self-Administered COVID-19 Therapy

PR-M10-20-12

Abbott Receives FDA Emergency Use Authorization for its COVID-19 Blood Test

FDA Approval

FDA Approves First Treatment for Ebola Virus

PR-M10-20-10

Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial

PR-M10-20-09

Leadership

SPI Pharma Appoints Scott Thomson as CEO

PR-M10-20-08

Investment

Abzena Invests $60m into cGMP Manufacturing Capacity

PR-M10-20-06

COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials

PR-M10-20-07

Funding

Avail Medsystems Raises $100 Million in Series B Funding Led by D1 Capital to Meet Demand for Procedural Telemedicine™ Technology for the Operating Room

PR-M10-20-05

Leadership

Kymanox Adds Top Experts in Human Factors to Enhance Combination Product Capabilities

PR-M10-20-05

Expansion

Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates

PR-M10-20-04

Wet Granulation

The Application of Mannitol In Wet Granulation

PAO-10-20-CL-01

Financing

Lucid Scientific Secures $3 Million in Series Seed Financing Led by Dynamk Capital

PR-M10-20-03

Breakthrough Therapy

Farxiga Granted Breakthrough Therapy Designation in U.S. for Chronic Kidney Disease

PR-M10-20-02

Cover story

Restarting a Manufacturing Campus and Revitalizing a Community

PAP-Q3-20-CL-016

Research

Georgia State Researchers Developing Tool to Predict Medication Response in Mental Health Patients

PR-M09-20-35

Clinical Trials

ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1

PR-M09-20-34

Glass Vials

SGD Pharma Extends Industry-Leading Ready-to-Use Molded Glass Vial Range With Introduction of EasyLyo and ISO20mm 50ml Sizes in Tray

PR-M09-20-33

Nice Insight Overview

The Benefits of Expanding OSD Capacity

PAP-Q3-20-NI-001

Equipment

Reshoring a Nation’s API and Pharmaceutical Production

PAP-Q3-20-CL-015

Microbiome CDMO

Extensive Experience Is Crucial to Speed to the Clinic and Market for Live Biotherapeutic Products

PAP-Q3-20-CL-004

Vaccine Distribution

Anticipating the Logistics of a COVID-19 Vaccination Effort

PAP-Q3-20-CL-010

1 194

»